HBM HLDGS LTD DL-000025 (F:6XY) — Market Cap & Net Worth
Market Cap & Net Worth: HBM HLDGS LTD DL-000025 (6XY)
HBM HLDGS LTD DL-000025 (F:6XY) has a market capitalization of $1.35 Billion (€1.15 Billion) as of May 6, 2026. Listed on the F stock exchange, this Germany-based company holds position #7837 globally and #1049 in its home market, demonstrating a -5.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HBM HLDGS LTD DL-000025's stock price €1.41 by its total outstanding shares 835561162 (835.56 Million).
HBM HLDGS LTD DL-000025 Market Cap History: 2021 to 2026
HBM HLDGS LTD DL-000025's market capitalization history from 2021 to 2026. Data shows growth from $810.79 Million to $1.38 Billion (7.57% CAGR).
HBM HLDGS LTD DL-000025 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HBM HLDGS LTD DL-000025's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6XY by Market Capitalization
Companies near HBM HLDGS LTD DL-000025 in the global market cap rankings as of May 6, 2026.
Key companies related to HBM HLDGS LTD DL-000025 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
HBM HLDGS LTD DL-000025 Historical Marketcap From 2021 to 2026
Between 2021 and today, HBM HLDGS LTD DL-000025's market cap moved from $810.79 Million to $ 1.38 Billion, with a yearly change of 7.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.38 Billion | +10.16% |
| 2025 | €1.25 Billion | +563.21% |
| 2024 | €188.53 Million | +27.81% |
| 2023 | €147.51 Million | -50.65% |
| 2022 | €298.92 Million | -63.13% |
| 2021 | €810.79 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of HBM HLDGS LTD DL-000025 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.35 Billion USD |
| MoneyControl | $1.35 Billion USD |
| MarketWatch | $1.35 Billion USD |
| marketcap.company | $1.35 Billion USD |
| Reuters | $1.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more